Biomarkers for Immune Checkpoint Inhibitor Response in NSCLC: Current Developments and Applicability

Tostes, Katiane; Siqueira, Aléxia Polo; Reis, Rui Manuel; Leal, Letícia Ferro; Arantes, Lídia Maria Rebolho Batista

doi:10.3390/ijms241511887

Cited by 11 publications

(6 citation statements)

References 155 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The main limitation of our study is the lack of consensus on the methodological aspects and normal values for the measurements. Nevertheless, we explored the intestinal tract microenvironment as a possible source of biomarkers due to the lack of biomarkers in other compartments [ 43 , 44 ].…”

Section: Discussionmentioning

confidence: 99%

Biomarkers of Immunotherapy Response in Patients with Non-Small-Cell Lung Cancer: Microbiota Composition, Short-Chain Fatty Acids, and Intestinal Permeability

Moratiel-Pellitero,

Zapata-García,

Gascón-Ruiz

et al. 2024

Cancers

View full text Add to dashboard Cite

Immune checkpoint inhibitors have been proposed as the standard treatment for different stages of non-small-cell lung cancer in multiple indications. Not all patients benefit from these treatments, however, and certain patients develop immune-related adverse events. Although the search for predictors of response to these drugs is a major field of research, these issues have yet to be resolved. It has been postulated that microbiota could play a relevant role in conditioning the response to cancer treatments; however, the human factor of intestinal permeability also needs to be considered as it is closely related to the regulation of host–microbiota interaction. In this article, we analyzed the possible relationship between the response to immune checkpoint inhibitors and the onset of immune-related adverse events, gut microbiota status, and intestinal membrane permeability. In a pioneering step, we also measured short-chain fatty acid content in feces. Although the correlation analyses failed to identify predictive biomarkers, even when all variables were integrated, our patients’ microbial gut ecosystems were rich and diverse, and the intestinal barrier’s integrity was preserved. These results add new knowledge on the composition of microbiota and its correlation with barrier permeability and short-chain fatty acids and suggest that more studies are required before these potential biomarkers can be incorporated into the clinical management of patients via immune checkpoint inhibitor treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Biomarkers of Immunotherapy Response in Patients with Non-Small-Cell Lung Cancer: Microbiota Composition, Short-Chain Fatty Acids, and Intestinal Permeability

Moratiel-Pellitero,

Zapata-García,

Gascón-Ruiz

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

“…The tumor-infiltrating lymphocytes (TILs), gut microbiome composition, gene expression profiles, biomarkers related to tumor metabolism, and gene expression profiling are among the additional biomarkers that are emerging for ICI response prediction ( 13 ).…”

Section: Discussionmentioning

confidence: 99%

Case report: Immunotherapy guided by molecular profiling of tumors: illustrative cases and literature review

Ozdogan,

Papadopoulou,

Metaxa-Mariatou

et al. 2024

Front. Med.

View full text Add to dashboard Cite

Predictive biomarkers are necessary for the identification of immunotherapy-responsive patients. Tumor mutation burden (TMB), as determined by next-generation sequencing (NGS), and PD-L1 expression, as evaluated by Immunohistochemistry (IHC), are the biomarkers most frequently employed in clinical practice. In addition, microsatellite instability (MSI) was the first biomarker to demonstrate immunotherapy efficacy irrespective of the type of tumor and possesses a high predictive value. However, its limited use across most tumor types limits its therapeutic potential. This report describes two cancer patients with positive TMB and PD-L1 expression. The molecular profile of the tumor indicated that the first patient was responsive to Immune checkpoint inhibitors (ICI), while the second patient was resistant. These case studies demonstrate that tumor molecular analysis in combination with immunotherapy predictive biomarkers, such as PD-L1 expression and TMB, can enhance the prediction of response to ICI for specific patients. This methodology enables an individualized and improved approach to the treatment and management of the disease.

show abstract

“…Currently, the PD-L1 expression is the most widely used biomarker in the clinic; however, its value as a predictive marker suffers at the hands of tumor heterogeneity as well as differences in defining those variable expression levels [ 162 , 164 ]. Several potential biomarkers in various stages of development propose a possible answer to this issue.…”

Section: Challenges and Future Directionsmentioning

confidence: 99%

Paracrine Regulation and Immune System Pathways in the Inflammatory Tumor Microenvironment of Lung Cancer: Insights into Oncogenesis and Immunotherapeutic Strategies

Batrash,

Shaik,

Rauf

et al. 2024

Cancers

View full text Add to dashboard Cite

The intricate interplay between inflammatory processes and the tumor microenvironment (TME) in lung cancer has garnered increasing attention due to its implications for both oncogenesis and therapeutic strategies. In this review, we explore recent advances in understanding the paracrine regulation and immune system pathways within the inflammatory TME of lung cancer. We delve into the molecular mechanisms underpinning oncogenesis, highlighting the role of immune cell populations, cancer-associated fibroblasts, and endothelial cells, as well as their interactions through immune system pathways regulated in a paracrine pattern. Additionally, we discuss emerging immunotherapeutic strategies with a specific focus on the potential of leveraging the inflammatory TME through these pathways to enhance treatment efficacy in lung cancer.

show abstract

Biomarkers for Immune Checkpoint Inhibitor Response in NSCLC: Current Developments and Applicability

Cited by 11 publications

References 155 publications

Biomarkers of Immunotherapy Response in Patients with Non-Small-Cell Lung Cancer: Microbiota Composition, Short-Chain Fatty Acids, and Intestinal Permeability

Biomarkers of Immunotherapy Response in Patients with Non-Small-Cell Lung Cancer: Microbiota Composition, Short-Chain Fatty Acids, and Intestinal Permeability

Case report: Immunotherapy guided by molecular profiling of tumors: illustrative cases and literature review

Paracrine Regulation and Immune System Pathways in the Inflammatory Tumor Microenvironment of Lung Cancer: Insights into Oncogenesis and Immunotherapeutic Strategies

Contact Info

Product

Resources

About